Recent approaches to novel antibacterials designed after LPS structure and biochemistry

Current Drug Targets

Volumn 13, Issue 11, 2012, Pages 1458-1471

  Gabrielli, Luca ^a   Capitoli, Alice ^a   Bini, Davide ^a   Taraballi, Francesca ^a   Lupo, Cristina ^a   Russo, Laura ^a   Cipolla, Laura ^a  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

Antibacterials; Gram negative bacteria; Kdo; LPS; Septic shock; Toll like receptor 4

Indexed keywords

ANTIINFECTIVE AGENT; AURANOFIN; BACTERIAL ENZYME; BACTERIUM LIPOPOLYSACCHARIDE; CD14 ANTIGEN; DALCETRAPIB; E 5531; ENDOTOXIN; ERITORAN; L 161240; LIPID A; N PYRENEMALEIMIDE; PROTEIN MD 2; RECEPTOR BLOCKING AGENT; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 4 ANTAGONIST; TU 517; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; BACTERIAL SURVIVAL; DRUG DESIGN; DRUG IDENTIFICATION; DRUG SYNTHESIS; DRUG TARGETING; ENZYME INHIBITION; ENZYME MECHANISM; GRAM NEGATIVE BACTERIUM; HUMAN; IC 50; INFLAMMATORY CELL; LIPOGENESIS; MOLECULAR INTERACTION; NONHUMAN; REVIEW; SEPTIC SHOCK; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ANTI-BACTERIAL AGENTS; CARBOHYDRATE CONFORMATION; LIPOPOLYSACCHARIDES;

EID: 84866916500     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945012803530242     Document Type: Review

References (153)

1. Christoffersen RE. Antibiotics-an investment worth making? Nat Biotechnol 2006; 24: 1512-4.
2. Nicolaou KC, Chen JS, Edmonds DJ, Entrada AA. Recent advances in the chemistry and biology of naturally occurring antibiotics. Angew Chem Int Ed 2009; 48: 660-719.
3. Barbachyn MR, Ford CW. Oxazolidinone structure-activity relationships leading to linezolid. Angew Chem Int Ed 2003; 42: 2010-23.
4. Minas W. Erythromycins. Enc. Ind. Biotechnol 2010; 4: 2310-24.
5. Singh SB, Barrett JF. Empirical antibacterial drug discovery-foundation in natural products. Biochem Pharmacol 2006; 71: 1006-15.
6. von Nussbaum F, Brands M, Hinzen B, Weigand S, Habich D. Antibacterial natural products in medicinal chemistry-exodus or revival? Angew Chem Int Ed 2006; 45: 5072-129.
7. Kirkpatrick P, Raja A, La Bonte J, Lebbos J. Daptomycin. Nat Rev Drug Discov 2003; 2: 943-4.
8. Alder JD. Daptomycin: a new drug class for the treatment of Grampositive infections. Drugs Today 2005; 41: 81-90.
9. Overbye KM, Barrett JF. Antibiotics: where did we go wrong?. Drug Discov Today 2005; 10: 45-52.
10. For a thematic issue on antibiotic resistance, see:Walsh CT, Wright G, editors. Chem. Rev 2005; 105: 391-774
11. Clark NM, Hershberger E, Zervosc MJ, Lynch JP 3rd. Antimicrobial resistance among gram-positive organisms in the intensive care unit. Curr Opin Crit Care 2003; 9: 403-12.
12. Taubes G. The Bacteria Fight Back. Science 2008; 321: 356-61.
13. Raetz CRH, Whitfield C. Lipopolysaccharide endotoxins. Annu Rev Biochem 2002; 71: 635-700.
14. Wang X, Quinn PJ. Lipopolysaccharide: Biosynthetic pathway and structure modification. Progress Lipid Res 2010; 49: 97-107.
15. Raetz CRH, Guan Z, Ingram BO, et al. Discovery of new biosynthetic pathways: the lipid A story. J Lipid Res 2009; 50: S103-S108.
16. Brandenburg K, Wiese A. Endotoxins: relationships between structure, function, and activity. Curr Top Med Chem 2004; 4: 1127-46.
17. Raetz CRH, Garrett TA, Reynolds CM, et al. Kdo2-Lipid A of Escherichia coli, a defined endotoxin that activates macrophages via TLR-4. J Lipid Res 2006; 47: 1097-111.
18. Raetz CRH, Reynolds CM, Trent MS, Bishop RE. Lipid a modification systems in gram-negative bacteria. Annu Rev Biochem 2007; 76: 295-329.
19. Mata-Haro V, Cekic C, Martin M, Chilton PM, Casella CR, Mitchell TC. The vaccine adjuvant monophosphoryl Lipid A as a TRIF-biased agonist of TLR4. Science 2007; 316: 1628-32.
20. Zimmer SM, Zughaier SM, Tzeng Y-L, Stephens DS. Human MD-2 discrimination of meningococcal lipid A structures and activation of TLR4. Glycobiology 2007; 17: 847-56.
21. Holst O. Chemical structure of the core region of lipopolysaccharidesan update. Trends Glycosci Glycotech 2002; 14: 87-103.
22. Holst O. The structures of core regions from enterobacterial lipopolysaccharides-an update. FEMS Microbiol Lett 2007; 271: 3-11.
23. Frirdich E, Bowman C, Vinogradov E, Whitfield C. The role of galacturonic acid in outer membrane stability in Klebsiella pneumoniae. J Biol Chem 2005; 280: 27604-12.
24. Angata T, Varki A. Chemical diversity in the sialic acids and related alfa-keto acids: an evolutionary perspective. Chem Rev 2002; 102: 439-69.
25. Nikaido H. Molecular basis of bacterial outer membrane permeability revisited. Microbiol Mol Biol Rev 2003; 67: 593-656.
26. Meredith TC, Aggarwal P, Mamat U, Lindner B, Woodard RW. Redefining the requisite lipopolysaccharide structure in Escherichia coli. ACS Chem Biol 2006; 1: 33-42.
27. Whitfield C. Biosynthesis and assembly of capsular polysaccharides in Escherichia coli. Annu Rev Biochem 2006; 75: 39-68.
28. Knirel YA, Dentovskaya SV, Senchenkova SN, Shaikhutdinova RZ, Kocharova NA, Anisimov AP. Structural features and structural variability of the lipopolysaccharide of Yersinia pestis, the cause of plague. J Endotoxin Res 2006; 12: 3-9.
29. Gronow S, Brade H. Lipopolysaccharide biosynthesis: which steps do bacteria need to survive? J Endotoxin Res 2001; 7: 3-23.
30. Yethon JA, Whitfield C. Lipopolysaccharide as a target for the development of novel therapeutics in Gram-negative bacteria. Curr Drug Targets-Infect Dis 2001; 1: 91-106.
31. Gibbons HS, Kalb SR, Cotter RJ, Raetz CRH. Role of Mg2+ and pH in the modification of Salmonella lipid A after endocytosis by macrophage tumour cells. Mol Microbiol 2005; 55: 425-40.
32. Bader MW, Sanowar S, Daley ME, et al. Recognition of antimicrobial peptides by a bacterial sensor kinase. Cell 2005; 122: 461-72.
33. Chng S-S, Gronenberg LS, Kahne D. Proteins Required for lipopolysaccharide assembly in Escherichia coli form a transenvelope complex. Biochemistry 2010; 49: 4565-7 and refs cited therein.
34. Reynolds CM, Raetz CRH. Replacement of lipopolysaccharide with free lipid A molecules in Escherichia coli mutants lacking all core sugars. Biochemistry 2009; 48: 9627-40.
35. Dotson GD, Dua RK, Clemens JC, Wooten EW, Woodard RW. Overproduction and one-step purification of Escherichia coli 3-deoxy-D-manno-octulosonic acid 8-phosphate synthase and oxygen transfer studies during catalysis using isotopic-shifted heteronuclear NMR. J Biol Chem 1995; 270: 13698-705.
36. Wu J, Woodard RW. Escherichia coli YrbI is 3-deoxy-d-mannooctulosonate 8-phosphate phosphatase. J Biol Chem 2003; 278: 18117-23.
37. Goldman RC, Kohlbrenner WE. Molecular cloning of the structural gene coding for CTP:CMP-3-deoxy-manno-octulosonate cytidylyltransferase from Escherichia coli K-12. J Bacteriol 1985; 163: 256-61.
38. King JD, Kocíncová D, Westman EL, Lam JS. Lipopolysaccharide biosynthesis in Pseudomonas aeruginosa. Innate Immunity 2009; 15: 261-312.
39. Belunis CJ, Mdluli KE, Raetz CRH, Nano FE. A novel 3-deoxy-Dmanno-octulosonic acid transferase from Chlamydia trachomatis required for expression of the genus-specific epitope. J Biol Chem 1992; 267: 18702-7.
40. Goldman RC, Bolling TJ, Kohlbrenner WE, Kim Y, Fox JL. Primary structure of CTP:CMP-3-deoxy-D-manno-octulosonate cytidylyltransferase (CMP-KDO synthetase) from Escherichia coli. J Biol Chem 1986; 261: 15831-5.
41. Meredith TC, Woodard RW. Identification of GutQ from Escherichia coli as a D-Arabinose 5-Phosphate Isomerase. J Bacteriol 2005; 187: 6936-42.
42. Meredith TC, Woodard RW. Escherichia coli YrbH Is a D-Arabinose 5-Phosphate Isomerase. J Biol Chem 2003; 278: 32771-7.
43. Meredith TC, Woodard RW. Characterization of Escherichia coli D-arabinose 5-phosphate isomerise encoded by kpsF: implications for group 2 capsule biosynthesis. Biochem J 2006; 395: 427-32.
44. Sperandeo P, Pozzi C, Dehò G, Polissi A. Non-essential KDO biosynthesis and new essential cell envelope biogenesis genes in the Escherichia coli yrbG-yhbG locus. Res Microbiol 2006; 157: 547-58.
45. Sommaruga S, De Gioia L, Tortora P, Polissi A. Structure prediction and functional analysis of KdsD, an enzyme involved in lipopolysaccharide biosynthesis. Biochem Biophys Res Commun 2009; 388: 222-7.
46. Taylor PL, Blakely KM, de Leon GP, et al. Structure and function of sedoheptulose-7-phosphate isomerase, a critical enzyme for lipopolysaccharide biosynthesis and a target for antbiotic adjuvants. J Biol Chem 2008; 283: 2835-45.
47. Airoldi C, Sommaruga S, Merlo S, et al. Targeting bacterial membranes: NMR characterization of substrate recognition and binding requirements of D-arabinose 5P Isomerase, a key enzyme in the biosynthesis of LPS. Chem Eur J 2010; 16: 1897-902.
48. Airoldi C, Sommaruga S, Merlo S, et al. Targeting bacterial membranes: identification of Pseudomonas aeruginosa D-arabinose-5P Isomerase and NMR characterisation of its substrate recognition and binding properties ChemBioChem 2011; 12: 719-27.
49. Hedstrom L, Abeles R. 3-Deoxy-D-manno-octulosonate-8-phosphate synthase catalyzes the C-O bond cleavage of phosphoenolpyruvate. Biochem Biophys Res Commun 1988; 157: 816-20.
50. Duewel HS, Woodard RW. A metal bridge between two enzyme families. 3-deoxy-D-manno-octulosonate-8-phosphate synthase from Aquifex aeolicus requires a divalent metal for activity. J Biol Chem 2000; 275: 22824-31.
51. Krosky DJ, Alm R, Berg M, et al. Helicobacter pylori 3-deoxy-Dmanno-octulosonate-8-phosphate (KDO-8-P) synthase is a zincmetalloenzyme. Biochim Biophys Acta 2002; 1594: 297-306.
52. Vainer R, Belakhov V, Rabkin E, Baasov T, Adir N. Crystal structures of Escherichia coli KDO8P Synthase complexes reveal the source of catalytic irreversibility. J Mol Biol 2005; 351: 641-52.
53. Shulami S, Furdui C, Adir N, Shoham Y, Anderson KS, Baasov T. A reciprocal single mutation affects the metal requirement of 3-deoxy-D-manno-2-octulosonate-8-phosphate (KDO8P) synthases from Aquifex pyrophilus and Escherichia coli. J Biol Chem 2004; 43: 45110-20.
54. Liang P-H, Kohen A, Baasov T, Anderson KS. Catalytic mechanism of KDO8P synthase: synthesis and evaluation of a putative reaction intermediate. Bioorg Med Chem Lett 1997; 7: 2457-62.
55. Li Z, Sau AK, Shen S, Whitehouse C, Baasov T, Anderson KS. A snapshot of enzyme catalysis using electrospray ionization mass spectrometry. J Am Chem Soc 2003; 125: 9938-9.
56. Kaustov L, Kababya S, Belakhov V, Baasov T, Shoham Y, Schmidt A. Inhibition mode of a bisubstrate inhibitor of KDO8P synthase: a frequency-selective REDOR solid-state and solution NMR characterization. J Am Chem Soc 2003; 125: 4662-9.
57. Furdui CM, Sau AK, Yaniv O, et al. The Use of (E)-and (Z)-phosphoenol-3-fluoropyruvate as mechanistic probes reveals significant differences between the active sites of KDO8P and DAHP Synthases. Biochemistry 2005; 44: 7326-35.
58. Ghalambor MA, Heath EC. The biosynthesis of cell wall lipopolysaccharide in Escherichia coli. V. Purification and properties of 3-deoxy-D-manno-octulosonate aldolase. J Biol Chem 1966; 241: 3222-7.
59. Berger H, Hammerschmid F. Isolation of 3-deoxy-2-octulosonate 8-phosphate phosphatase, a new specific enzyme in the biosynthesis of lipopolysaccharide. Biochem Soc Trans 1975; 3: 1096-7.
60. Ray PH, Benedict CD. Purification and characterization of specific 3-deoxy-D-manno-octulosonate 8-phosphate phosphatase from Escherichia coli B. J Bacteriol 1980; 142: 60-8.
61. Biswas T, Yi L, Aggarwal P, et al. The tail of KdsC conformational changes control the activity of a haloacid dehalogenase superfamily phosphatise J Biol Chem 2009; 284: 30594-603.
62. Parsons JF, Lim K, Tempczyk A, et al. From structure to function: YrbI From Haemophilus influenzae (HI1679) is a phosphatase. Proteins 2002; 46: 393-404.
63. Kuznetsova E, Proudfoot M, Gonzalez CF, et al. Genome-wide analysis of substrate specificities of the Escherichia coli haloacid dehalogenase-like phosphatase family. J Biol Chem 2006; 281: 36149-61.
64. Cho H, Wang W, Kim R, et al. BeF(3)(-) acts as a phosphate analog in proteins phosphorylated on aspartate: structure of a BeF(3)(-) complex with phosphoserine phosphatase. Proc Natl Acad Sci USA 2001; 98: 8525-30.
65. Allen KN, Dunaway-Mariano D. Phosphoryl group transfer: evolution of a catalytic scaffold. Trends Biochem Sci 2004; 29: 495-503.
66. Wagner GK, Pesnot T, Field RA. A survey of chemical methods for sugar-nucleotide synthesis. Nat Prod Rep 2009; 26: 1172-94.
67. Jann K, Jann B. Capsules of Escherichia coli, expression and biological significance. Can J Microbiol 1992; 38: 705-10.
68. Jelakovic S, Schulz GE. Catalytic mechanism of CMP:2-keto-3-deoxy-manno-octonic acid synthetase as derived from complexes with reaction educt and product Biochemistry 2002; 41: 1174-81.
69. Ku MJ, Yoon HJ, Ahn HJ, Kim HW, Baek SH, Suh SW. Crystallization and preliminary X-ray crystallographic studies of 3-deoxymanno-octulosonate cytidylyltransferase from Haemophilus influenzae. Acta Crystallogr D Biol Crystallogr 2003; 59: 180-2.
70. Yoon H-J, Ku M-J, Mikami B, Suh SW. Structure of 3-deoxymanno-octulosonate cytidylyltransferase from Haemophilus influenzae complexed with the substrate 3-deoxy-mannooctulosonate in the β-configuration. Acta Cryst 2008; D64: 1292-4.
71. Badger J, Sauder M, Adams JM, et al. Structural analysis of a set of proteins resulting from a bacterial genomics project. Proteins 2005; 60: 787-96.
72. Heyes DJ, Levy C, Lafite P, et al. Structure-based mechanism of CMP-2-keto-3-deoxymanno-octulonic acid synthetase: convergent evolution of a sugar-activating enzyme with DNA/RNA polymerases. J Biol Chem 2009; 284: 35514-23.
73. Claesson K, Luthman K, Gustafsson K, Bondesson G. A 2-deoxy analogue of KDO as the first inhibitor of the enzyme CMP-KDO synthetase. Biochem. Biophys Res Commun 1987; 143: 1063-8.
74. Cipolla L, Gabrielli L, Bini D, Russo L, Shaikh N. Kdo: a critical monosaccharide for bacteria viability. Nat Prod Rep 2010; 27: 1618-29.
75. Mamat U, Meredith TC, Aggarwal P, et al. Single amino acid substitutions in either YhjD or MsbA confer viability to 3-deoxy-dmanno-oct-2-ulosonic acid-depleted Escherichia coli. Mol Microbiol 2008; 67: 633-48.
76. Kondo K-I, Doi H, Adachi H, Nishimura Y. Synergistic effect of CMP/KDO synthase inhibitors with antimicrobial agents on inhibition of production and release of vero toxin by enterohaemorrhagic Escherichia coli O157:H7. Bioorg Med Chem Lett 2004; 14: 467-70.
77. Reviewed in Cipolla L, Polissi A, Airoldi C, Gabrielli L, Merlo S, Nicotra F. New targets for antibacterial design: Kdo biosynthesis and LPS machinery transport to the cell surface. Curr Med Chem 2011; 18: 830-52.
78. Yep A, Sorenson RJ, Wilson MR, et al. Enediol mimics as inhibitors of the D-arabinose 5-phosphate isomerase (KdsD) from Francisella tularensis. Bioorg Med Chem Lett 2011; 21: 2679-82.
79. Belakhov V, Dovgolevsky E, Rabkin E, Shulami S, Shoham Y, Baasov T. Synthesis and evaluation of a mechanism-based inhibitor of KDO8P synthase. Carbohydr Res 2004; 339: 385-392.
80. Birck MR, Holler TP, Woodard RV. Identification of a slow tightbinding inhibitor of 3-deoxy-d-manno-octulosonic acid 8-phosphate synthase. J Am Chem Soc 2000; 122: 9334-35.
81. Adachi H, Kondo KI, Kojima F, et al. Synthesis and inhibitory activity of 8-substituted 2-deoxy-beta-KDO against CMP-KDO synthetase. Nat Prod Res Part B: Bioactive Nat Prod 2006; 20: 361-70.
82. Raetz CRH, Roderick SL. A left-handed parallel beta helix in the structure of UDP-N-acetylglucosamine acyltransferase. Science 1995; 270: 997-1000
83. Wyckoff TJ, Raetz CRH. The active site of Escherichia coli UDPN-acetylglucosamine acyltransferase. Chemical modification and site-directed mutagenesis. J Biol Chem 1999; 274: 27047-27055.
84. Coggins BE, Li X, McClerren AL, et al. Structure of the LpxC deacetylase with a bound substrate-analog inhibitor. Nat Struct Biol 2003; 10: 645-51.
85. Whittington DA, Rusche KM, Shin H, Fierke CA, Christianson DW. Crystal structure of LpxC, a zinc-dependent deacetylase essential for endotoxin biosynthesis. Proc Natl Acad Sci USA 2003; 100: 8146-50.
86. Gennadios HA, Whittington DA, Li X, Fierke CA, Christianson DW. Mechanistic inferences from the binding of ligands to LpxC, a metal-dependent deacetylase. Biochemistry 2006; 45: 7940-8.
87. Buetow L, Smith TK, Dawson A, Fyffe S, Hunter WN. Structure and reactivity of LpxD, the N-acyltransferase of lipid A biosynthesis. Proc Natl Acad Sci USA 2007; 104: 4321-6.
88. Jackman JE, Raetz CRH, Fierke CA. Site-directed mutagenesis of the bacterial metalloamidase UDP-(3-O-acyl)-N-acetylglucosamine deacetylase (LpxC). Identification of the zinc binding site. Biochemistry 2001; 40: 514-23.
89. Onishi HR, Pelak BA, Gerckens LS, et al. Antibacterial agents that inhibit Lipid A biosynthesis. Science 1996; 274: 980-2.
90. Jackman JE, Fierke CA, Tumey LN, et al. Antibacterial agents that target lipid a biosynthesis in gram-negative bacteria: inhibition of diverse UDP-3-O-(R-3-hydroxymyristoyl)-n-acetylglucosamine deacetylases by substrate analogs containing zinc binding motifs. J Biol Chem 2000; 275: 11002-9.
91. Belunis CJ, Raetz CR. Biosynthesis of endotoxins purification and catalytic propreties of deoxy-D-manno-octolusonic acid transferase from Escherichia Coli. J Biol Chem 1992; 267: 9988-97.
92. Bode CE, Brabetz W, Brade H. Cloning and characterization of 3-deoxy-d-manno-oct-2-ulosonic acid (Kdo) transferase genes (kdtA) from Acinetobacter baumannii and Acinetobacter haemolyticus. Eur J Biochem 1998; 254: 404-12.
93. Lobau S, Mamat U, Brabetz W, Brade H. Molecular cloning, sequence analysis, and functional characterization of the lipopolysaccharide biosynthetic gene kdtA encoding 3-deoxy-alpha-D-mannooctulosonic acid transferase of Chlamydia pneumoniae strain TW-183. Mol Microbiol 1995; 18: 391-9.
94. Wong CH, Hayashi T PCT Int. Appl. (1998), WO 9825940 A1 19980618 Application: WO 97-US22713 19971210.
95. Tokuda H, Matsuyama S. Sorting of lipoproteins to the outer membrane in E. coli. Biochim Biophys Acta 2004; 1693: 5-13.
96. Ulevitch RJ, Tobias PS. Receptor-dependent mechanisms of cell stimulation by bacterial endotoxin. Annu Rev Immunol 1995; 13: 437-57.
97. Kim HM, Park BS, Kim J-I, et al. Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran. Cell 2007; 130: 906-17.
98. Ohto U, Fukase K, Miyake K, Satow Y. Crystal structures of human MD-2 and its complex with antiendotoxic lipid IVa. Science 2007; 316: 16324.
99. Miyake K. Innate recognition of lipopolysaccharide by Toll-like receptor 4-MD-2. Trends Microbiol 2004; 12: 186-92.
100. Munford RS, Varley AW. Shield as signal: lipopolysaccharides and the evolution of immunity to gram-negative bacteria. PLOS Pathogens 2006; 2: 467-71.
101. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29: 1303-10.
102. Park BS, Song DH, Kim HM, Choi BS, Lee H, Lee JO. The structural basis of lipopolysaccharide recognitionby the TLR4-MD-2 complex. Nature 2009; 458: 1191-5.
103. Jin MS, Kim ES, Heo JY, et al. Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-acylated lipopeptide. Cell 2007; 130: 1071-82.
104. Liu L, Botos I, Wang Y, et al. Structural basis of toll-like receptor 3 signaling with double-stranded RNA. Science 2008; 320: 379-81.
105. Christ WJ, Rossignol DP, Kobayashi S, Kawata T. Substituted lipopolysaccharides useful in the treatment and prevention of endotoxemia. U.S. Patent 5935938, August 10, 1999.
106. Lynn M., Rossignol DP, Wheeler JL, et al. Blocking of responses to endotoxin by E5564 in healthy volunteers with experimental endotoxemia. J Infect Dis 2003; 187: 631-9.
107. Alexander C, Zahringer U. Chemical structure of lipid A-the primary immunomodulatory center of bacterial lipopolysaccharides. Trends Glycosci Glycotechnol 2002; 14: 69-86.
108. Viriyakosol S, Tobias PS, Ketchens RL, Kirkland TN. MD-2 binds to bacterial lipopolysaccharide. J Biol Chem 2001; 276: 38044-51.
109. Poltorak A, Ricciardi-Castagnoli P, Citterio S, Beutler B. Physical contact between lipopolysaccharide and toll-like receptor 4 revealed by genetic complementation. Proc Natl Acad Sci USA 2000; 97: 2163-67.
110. Lien E, Means TK, Heine H, et al. Toll-like receptor 4 imparts ligand-specific recognition of bacterial lipopolysaccharide. J Clin Invest 2000; 105: 497-504.
111. Muroi M, Ohnishi T, Tanamoto K. MD-2, a novel accessory molecule, is involved in species-specific actions of salmonella lipid A. Infect Immun 2002; 70: 3546-50.
112. Montminy SW, Khan N, McGrath S, et al. Virulence factors of Yersinia pestis are overcome by a strong lipopolysaccharide response. Nat Immunol 2006; 7: 1066-73.
113. Brandenburg K, Andrä J, Müller M, Koch MH, Garidel P. Physicochemical properties of bacterial glycopolymers in relation to bioactivity. Carbohydr Res 2003; 338: 2477-89.
114. Kusumoto S, Fukase K, Fukase Y, et al. Structural basis for endotoxic and antagonistic activities: investigation with novel synthetic lipid A analogs Endotoxin Res 2003; 9: 361-66.
115. Means TK, Golenbock DT, Fenton MJ. The biology of toll-like receptors. Cytokine Growth Factor Rev 2000; 11: 219-32.
116. Peri F, Piazza M. Therapeutic targeting of innate immunity with Toll-like receptor 4 (TLR4) antagonists. Biotechnol Adv 2011;DOI: 10.1016/j.biotechadv.2011.05.014.
117. Loppnow H, Libby P, Freudenberg M, Krauss JH, Weckesser J, Mayer H. Cytokine induction by lipopolysaccharide (LPS) corresponds to lethal toxicity and is inhibited by nontoxic Rhodobacter capsulatus LPS. Infect Immun 1990; 58: 3743-50.
118. Christ W, Asano O, Robidoux A, et al. E5531, a pure endotoxin antagonist of high potency. Science 1995; 268: 80-3.
119. Wasan K, Strobel F, Parrott S, et al. Lipoprotein distribution of a novel endotoxin antagonist, E5531, in plasma from human subjects with various lipid levels. Antimicrob Agents Chemother 1999; 43: 2562-4.
120. Barochia A, Solomon S, Cui X, Natanson C, Eichacker PQ. Eritoran tetrasodium (E5564) treatment for sepsis: review of preclinical and clinical studies. Expert Opin Drug Metab Toxicol 2011; 7: 479-94.
121. Tidswell M, Tillis W, Larosa SP, et al. Phase 2 trial of eritoran tetrasodium (E5564), a tolllike receptor 4 antagonist, in patients with severe sepsis. Crit Care Med 2010; 38: 72-83
122. Rossignol D, Lynn M. Antagonism of in vivo and ex vivo response to endotoxin by E5564, a synthetic lipid A analogue. J Endotoxin Res 2002; 8: 483-8.
123. Mullarkey M, Rose J, Bristol J, et al. Inhibition of endotoxin response by E5564, a novel Toll-like receptor 4-directed endotoxin antagonist. J Pharmacol Exp Ther 2003; 304: 1093-102.
124. Piazza M, Rossini C, Della Fiorentina S, et al. Glycolipids and benzylammonium lipids as novel antisepsis agents: synthesis and biological characterization. J Med Chem 2009; 52: 1209-13.
125. Piazza M, Yu L, Teghanemt A, et al. Evidence of a specific interaction between new synthetic antisepsis agents and CD14. Biochemistry 2009; 48: 12337-44.
126. van der Poll T. Opal SM Host-pathogen interactions in sepsis. Lancet Infect Dis 2008; 8: 32-43.
127. Nascimento DC, Alves-Filho JC, Sonego F, et al. Role of regulatory T cells in long-term immune dysfunction associated with severe sepsis. Crit Care Med 2010; 38: 1718-25.
128. Tang BM, Huang SJ, McLean AS. Genome-wide transcription profiling of human sepsis: a systematic review. Crit Care 2010; 14: R237.
129. Delano MJ, Thayer T, Gabrilovich S, et al. Sepsis induces early alterations in innate immunity that impact mortality to secondary infection. J Immunol 2011; 186: 195-202.
130. Todd W. Rice and Gordon R. Bernard Therapeutic intervention and targets for sepsis Annu Rev Med 2005; 56: 225-48.
131. Huttunen R, Aittoniemi J New concepts in the pathogenesis, diagnosis and treatment of bacteremia and sepsis. J Infect 2011; 63: 407-19.
132. Burns K, Janssens S, Brissoni B, Olivos N, Beyaert R, Tschopp J. Inhibition of interleukin 1 receptor/Toll-like receptor signaling through the alternatively spliced, short form of MyD88 is due to its failure to recruit IRAK-4. J Exp Med 2003; 197: 263-8.
133. Sweet MJ, Leung BP, Kang D, et al. A novel pathway regulating lipopolysaccharide-induced shock by ST2/T1 via inhibition of Tolllike receptor 4 expression. J Immunol 2001; 166: 6633-9.
134. Haziot A, Rong GW, Lin XY, Silver J, Goyert SM. Recombinant soluble CD14 prevents mortality in mice treated with endotoxin (lipopolysaccharide). J Immunol 1995; 154: 6529-32.
135. Reinhart K, Gluck T, Ligtenberg J, et al. CD14 receptor occupancy in severe sepsis: results of a phase I clinical trial with a recombinant chimeric evolving concepts associated with sepsis CD14 monoclonal antibody (IC14). Crit Care Med 2004; 32: 1100-8.
136. Matthews RC, Rigg G, Hodgetts S, et al. Preclinical assessment of the efficacy of mycograb, a human recombinant antibody against fungal HSP90. Antimicrob Agents Chemother 2003; 47: 2208-16.
137. Pachl J, Svoboda P, Jacobs F, et al. A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein in patients with invasive candidiasis. Clin Infect Dis 2006; 42: 1404-13.
138. Brahmamdam P, Inoue S, Unsinger J, Chang KC, McDunn JE, Hotchkiss RS. Delayed administration of anti-PD-1 antibody reverses immune dysfunction and improves survival during sepsis. J Leukoc Biol 2010; 88: 233-40.
139. Zhang Y, Zhou Y, Lou J, et al. PD-L1 blockade improves survival in experimental sepsis by inhibiting lymphocyte apoptosis and reversing monocyte dysfunction. Crit Care 2010; 14: R220.
140. Inoue S, Bo L, Bian J, Unsinger J, Chang K, Hotchkiss RS. Dose Dependent Effect of Anti-CTLA-4 on Survival in Sepsis. Shock 2011; 36: 38-44.
141. Shui JW, Steinberg MW, Kronenberg M. Regulation of inflammation, autoimmunity, and infection immunity by HVEM-BTLA signaling. J Leukoc Biol 2011; 89: 517-23.
142. Gutsmann T, Razquin-Olazaran I, Kowalski I, et al. New antiseptic peptides to protect against endotoxin-mediated shock. Antimicrob Agents Chemother 2010; 54: 3817-24
143. Davies B, Cohen J. Endotoxin removal devices for the treatment of sepsis and septic shock. Lancet Infect Dis 2011; 11: 65-71.
144. Cauwels A, Buys ES, Thoonen R, et al. Nitrite protects against morbidity and mortality associated with TNF-or LPS-induced shock in a soluble guanylate cyclase-dependent manner. J Exp Med 2009; 206: 2915-24.
145. Sprung CL, Annane D, Keh D, et al. Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008; 358: 111-24.
146. Patel GP, Balk RA. Systemic Steroids in Severe Sepsis and Septic Shock. Am J Respir Crit Care Med 2012; 185: 133-9.
147. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699-709.
148. Janda S, Young A, Fitzgerald JM, Etminan M, Swiston J. The effect of statins on mortality from severe infections and sepsis: a systematic review and meta-analysis. J Crit Care 2010; 25: 656e7-22.
149. Kreymann KG, de Heer G, Nierhaus A, Kluge S. Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock. Crit Care Med 2007; 35: 2677-85
150. Norrby-Teglund A, Haque KN, Hammarstrom L. Intravenous polyclonal IgM-enriched immunoglobulin therapy in sepsis: a review of clinical efficacy in relation to microbiological aetiology and severity of sepsis. J Intern Med 2006; 260: 509-16.
151. Kasten KR, Prakash PS, Unsinger J, et al. Interleukin-7 (IL-7) treatment accelerates neutrophil recruitment through gamma deltaT-cell IL-17 production in a murine model of sepsis. Infect Immun 2010; 78: 4714-22.
152. Inoue S, Unsinger J, Davis CG, et al. IL-15 prevents apoptosis, reverses innate and adaptive immune dysfunction, and improves survival in sepsis. J Immunol 2010; 184: 1401-9.
153. Maiti KK, DeCastro M, El-Sayed AB, Foote MI, Wolfert MA, Boons GJ. Chemical Synthesis and Proinflammatory Responses of Monophosphoryl Lipid A Adjuvant Candidates. Eur J Org Chem 2010; 80-91.